Lenalidomide in relapsed or refractory mantle cell lymphoma: Overview and perspective

Therapeutic Advances in Hematology

Volumn 5, Issue 3, 2014, Pages 91-101

  Desai, Madhav ^a   Newberry, Kate ^a   Zhishuo, Z ^a   Wang, Michael ^a   Zhang, Liang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

immunomodulatory agents; lenalidomide; mantle cell lymphoma

Indexed keywords

EID: 84993815526     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714532124     Document Type: Review

References (67)

1. Ansell S. Inwards D. Rowland K. Jr. Flynn P. Morton R. Moore D. Jr. et al. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 113: 508–514.
2. Ansell S. Tang H. Kurtin P. Koenig P. Inwards D. Shah K. et al. (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12: 361–368.
3. Aragon-Ching J. Li H. Gardner E. Figg W. (2007) thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2: 167–174.
4. Attal M. Lauwers-Cances V. Marit G. Caillot D. Moreau P. Facon T. et al. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782–1791.
5. Bartlett J. Dredge K. Dalgleish A. (2004) The evolution of thalidomide and its imid derivatives as anticancer agents. Nat Rev Cancer 4: 314–322.
6. Carrier M. Le Gal G. Tay J. Wu C. Lee A. (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9: 653–663.
7. Chanan-Khan A. Cheson B. (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26: 1544–1552.
8. Chaudhry V. Cornblath D. Corse A. Freimer M. Simmons-O'Brien E. Vogelsang G. (2002) Thalidomide-induced neuropathy. Neurology 59: 1872–1875.
9. Damaj G. Lefrere F. Delarue R. Varet B. Furman R. Hermine O. (2003) Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17: 1914–1915.
10. Damon L. Johnson J. Niedzwiecki D. Cheson B. Hurd D. Bartlett N. et al. (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27: 6101–6108.
11. Delarue R. Haioun C. Ribrag V. Brice P. Delmer A. Tilly H. et al. (2008) RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. ASH Annual Meeting Abstracts 112: 581.
12. Dredge K. Horsfall R. Robinson S. Zhang L. Lu L. Tang Y. et al. (2005) Orally Administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and AKT phosphorylation in vitro. Microvasc Res 69: 56–63.
13. Dredge K. Marriott J. Macdonald C. Man H. Chen R. Muller G. et al. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87: 1166–1172.
14. Eve H. Carey S. Richardson S. Heise C. Mamidipudi V. Shi T. et al. (2012) Single-agent lenalidomide in relapsed / refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 159: 154–163.
15. Fisher R. Bernstein S. Kahl B. Djulbegovic B. Robertson M. de Vos S. et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867–4874.
16. Flinn I. Mainwaring M. Peacock N. Shipley D. Arrowsmith E. Savona M. et al. (2012) Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma a phase I / II trial. ASH Annual Meeting Abstracts 120: 2748.
17. Foran J. Cunningham D. Coiffier B. Solal-Celigny P. Reyes F. Ghielmini M. et al. (2000) Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 11(Suppl. 1): 117–121.
18. Gaidarova S. Corral L. Gleizer E. Young D. Brady H. Bennett B. et al. (2008) Lenalidomide enhances anti-tumor effect of {gamma}{delta} T cells against mantle cell lymphoma. ASH Annual Meeting Abstracts 112: 2616.
19. Gaidarova S. Corral L. Glezer E. Schafer P. Lopez-Girona A. (2009) Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. ASH Annual Meeting Abstracts 114: 1687.
20. Gaidarova S. Mendy D. Heise C. Aukerman S. Daniel T. Chopra R. et al. (2010) Lenalidomide induces capping of CD20 and cytoskeleton proteins to enhance rituximab immune recognition of malignant B-cells. ASH Annual Meeting Abstracts 116: 2845.
21. Geisler C. Kolstad A. Laurell A. Andersen N. Pedersen L. Jerkeman M. et al. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687–2693.
22. Ghielmini M. Schmitz S. Cogliatti S. Bertoni F. Waltzer U. Fey M. et al. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23: 705–711.
23. Goy A. Sinha R. Williams M. Kalayoglu Besisik S. Drach J. Ramchandren R. et al. (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 31: 3688–3695.
24. Habermann T. Lossos I. Justice G. Vose J. Wiernik P. Mcbride K. et al. (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145: 344–349.
25. Hernandez-Ilizaliturri F. Reddy N. Holkova B. Ottman E. Czuczman M. (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11: 5984–5992.
26. Herrmann A. Hoster E. Zwingers T. Brittinger G. Engelhard M. Meusers P. et al. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27: 511–518.
27. Hess G. Herbrecht R. Romaguera J. Verhoef G. Crump M. Gisselbrecht C. et al. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822–3829.
28. Jerkeman M. Kolstad A. Laurell A. Raty R. Gronbaek K. Pedersen L. et al. (2011) Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCl 4 (LENA-BERIT) trial. ASH Annual Meeting Abstracts 118: 2700.
29. Kaufmann H. Raderer M. Wohrer S. Puspok A. Bankier A. Zielinski C. et al. (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed / refractory mantle cell lymphoma. Blood 104: 2269–2271.
30. Keifer J. Guttridge D. Ashburner B. Baldwin A. Jr. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of ikappab kinase activity. J Biol Chem 276: 22382–22387.
31. Khouri I. Romaguera J. Kantarjian H. Palmer J. Pugh W. Korbling M. et al. (1998) Hyper-CVAD and high-dose methotrexate / cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16: 3803–3809.
32. Kluin-Nelemans H. Hoster E. Hermine O. Walewski J. Trneny M. Geisler C. et al. (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367: 520–531.
33. Knight R. (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32: S24–S30.
34. Kumar S. Witzig T. Rajkumar S. (2002) Thalidomide as an anti-cancer agent. J Cell Mol Med 6: 160–174.
35. Lenz G. Dreyling M. Hoster E. Wormann B. Duhrsen U. Metzner B. et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–1992.
36. Menon S. Rajkumar S. Lacy M. Falco P. Palumbo A. (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112: 1522–1528.
37. Mileshkin L. Stark R. Day B. Seymour J. Zeldis J. Prince H. (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24: 4507–4514.
38. Moros A. Saborit-Villarroya I. Perez-Galan P. Martinez A. Campo E. Colomer D. et al. (2012) Activity of lenalidomide in vitro and in vivo models of bortezomib-resistant mantle cell lymphoma involving the modulation of c-myc/p27 axis. Cancer Res 72(8 Suppl): abstract 1942:
39. Morrison V. Jung S.-H. Johnson J. Lacasce A. Blum K. Bartlett N. et al. (2012) Salvage therapy with bortezomib plus lenalidomide for relapsed / refractory mantle cell lymphoma: initial results of a phase II trial (ALLIANCE/CALGB 50501). ASH Annual Meeting Abstracts 120: 3696.
40. Nickenig C. Dreyling M. Hoster E. Pfreundschuh M. Trumper L. Reiser M. et al. (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107: 1014–1022.
41. Palumbo A. Cavo M. Bringhen S. Zamagni E. Romano A. Patriarca F. et al. (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29: 986–993.
42. Perez-Galan P. Dreyling M. Wiestner A. (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117: 26–38.
43. Qian Z. Zhang L. Cai Z. Sun L. Wang H. Yi Q. et al. (2011) Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia Res 35: 380–386.
44. Reddy N. Hernandez-Ilizaliturri F. Czuczman M. (2006) The use of the immunomodulatory drug, lenalidomide (Revlimid(r)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. AACR Meeting Abstracts 2006: 154-a.
45. Reddy N. Hernandez-Ilizaliturri F. Deeb G. Roth M. Vaughn M. Knight J. et al. (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140: 36–45.
46. Reeder C. Witzig T. Zinzani P. Vose J. Buckstein R. Haioun C. et al. (2009) Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003). J Clin Oncol 27(Suppl. 15): abstract 8569.
47. Richardson P. Schlossman R. Weller E. Hideshima T. Mitsiades C. Davies F. et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067.
48. Richardson S. Eve H. Copplestone J. Dyer M. Rule S. (2010) Activity of thalidomide and lenalidomide in mantle cell lymphoma. Acta Haematol 123: 21–29.
49. Robinson K. Williams M. van der Jagt R. Cohen P. Herst J. Tulpule A. et al. (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26: 4473–4479.
50. Romaguera J. Fayad L. Feng L. Hartig K. Weaver P. Rodriguez M. et al. (2010) Ten-year follow-up after intense chemoimmunotherapy with rituximab-hypercvad alternating with rituximab-high dose methotrexate / cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150: 200–208.
51. Ruan J. Martin P. Shah B. Schuster S. Smith S. Furman R. et al. (2013) Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi-center phase II study of lenalidomide plus rituximab. Blood 122: 247.
52. Rummel M. Al-Batran S. Kim S. Welslau M. Hecker R. Kofahl-Krause D. et al. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23: 3383–3389.
53. Song K. Herzog B. Sheng M. Fu J. Mcdaniel J. Ruan J. et al (2013) Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res 73: 7254–7264.
54. Vallet S. Palumbo A. Raje N. Boccadoro M. Anderson K.C. (2008) Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 49: 1238–1245.
55. Vose J. Habermann T. Czuczman M. Zinzani P. Reeder C. Tuscano J. et al. (2013) Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 162: 639–647.
56. Wang M. Dimopoulos M. Chen C. Cibeira M. Attal M. Spencer A. et al. (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112: 4445–4451.
57. Wang M. Fayad L. Wagner-Bartak N. Zhang L. Hagemeister F. Neelapu S. et al. (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1 / 2 clinical trial. Lancet Oncol 13: 716–723.
58. Wang M. Rule S. Martin P. Goy A. Auer R. Kahl B. et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516.
59. Weber D. Chen C. Niesvizky R. Wang M. Belch A. Stadtmauer E. et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133–2142.
60. Wiernik P. Lossos I. Tuscano J. Justice G. Vose J. Cole C. et al. (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26: 4952–4957.
61. Witzig T. Geyer S. Ghobrial I. Inwards D. Fonseca R. Kurtin P. et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347–5356.
62. Witzig T. Vose J. Zinzani P. Reeder C. Buckstein R. Polikoff J. et al. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22: 1622–1627.
63. Zaja F. de Luca S. Vitolo U. Orsucci L. Levis A. Salvi F. et al. (2012) Salvage treatment with lenalidomide and dexamethasone in relapsed / refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 97: 416–422.
64. Zhang L. Qian Z. Cai Z. Sun L. Wang H. Bartlett J. et al. (2009) Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84: 553–559.
65. Zhou Y. Wang H. Fang W. Romaguer J. Zhang Y. Delasalle K. et al. (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113: 791–798.
66. Zhu D. Corral L. Fleming Y. Stein B. (2008) Immunomodulatory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57: 1849–1859.
67. Zinzani P. Vose J. Czuczman M. Reeder C. Haioun C. Polikoff J. et al. (2013) Long-term follow-up of lenalidomide in relapsed / refractory mantle cell lymphoma: subset analysis of the NHL-003 Study. Ann Oncol 24: 2892–2897.